1
|
Watanabe H: Mass screening program for
prostatic cancer in Japan. Int J Clin Oncol. 6:66–73.
2001.PubMed/NCBI
|
2
|
Ogawa K, Nakamura K, Onishi H, et al:
Japanese Patterns of Care Study Working Subgroup of Prostate
Cancer: Radical external beam radiotherapy for prostate cancer in
Japan: results of the 1999–2001 patterns of care process survey.
Jpn J Clin Oncol. 36:40–45. 2006. View Article : Google Scholar : PubMed/NCBI
|
3
|
Marugame T and Mizuno S: Comparison of
prostate cancer mortality in five countries: France, Italy, Japan,
UK and USA from the WHO mortality database (1960–2000). Jpn J Clin
Oncol. 35:690–691. 2005. View Article : Google Scholar : PubMed/NCBI
|
4
|
Bolla M, Van Tienhoven G, Warde P, et al:
External irradiation with or without long-term androgen suppression
for prostate cancer with high metastatic risk: 10-year results of
an EORTC randomised study. Lancet Oncol. 11:1066–1073. 2010.
View Article : Google Scholar : PubMed/NCBI
|
5
|
D'Amico AV, Chen MH, Renshaw AA, Loffredo
M and Kantoff PW: Androgen suppression and radiation vs. radiation
alone for prostate cancer: a randomized trial. JAMA. 299:289–295.
2008.PubMed/NCBI
|
6
|
Jones CU, Hunt D, McGowan DG, et al:
Radiotherapy and short-term androgen deprivation for localized
prostate cancer. N Engl J Med. 365:107–118. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
D'Amico AV, Denham JW, Crook J, et al:
Influence of androgen suppression therapy for prostate cancer on
the frequency and timing of fatal myocardial infarctions. J Clin
Oncol. 25:2420–2425. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo
RG, Eisenberg D and Pollack A: Long-term androgen deprivation
increases Grade 2 and higher late morbidity in prostate cancer
patients treated with three-dimensional conformal radiation
therapy. Int J Radiat Oncol Biol Phys. 62:397–405. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Bolla M, de Reijke TM, Van Tienhoven G, et
al: EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer
Group: Duration of androgen suppression in the treatment of
prostate cancer. N Engl J Med. 360:2516–2527. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kuban DA, Thames HD, Levy LB, et al:
Long-term multi-institutional analysis of stage T1-T2 prostate
cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol
Biol Phys. 57:915–928. 2003. View Article : Google Scholar : PubMed/NCBI
|
11
|
Sobin LH and Wittekind CH; International
Union Against Cancer (UICC). TNM Classification of Malignant
Tumors. 6th. Wiley; New York, NY: 2002
|
12
|
Roach M III, Hanks G, Thames H Jr, et al:
Defining biochemical failure following radiotherapy with or without
hormonal therapy in men with clinically localized prostate cancer:
recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int
J Radiat Oncol Biol Phys. 65:965–974. 2006. View Article : Google Scholar : PubMed/NCBI
|
13
|
Trotti A, Colevas AD, Setser A, et al:
CTCAE v3.0: development of a comprehensive grading system for the
adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
14
|
Oken MM, Creech RH, Tormey DC, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
15
|
Epstein JI, Allsbrook WC Jr, Amin MB and
Egevad LL: ISUP Grading Committee: The 2005 International Society
of Urological Pathology (ISUP) Consensus Conference on Gleason
Grading of Prostatic Carcinoma. Am J Surg Pathol. 29:1228–1242.
2005. View Article : Google Scholar : PubMed/NCBI
|
16
|
Mottet N, Peneau M, Mazeron JJ, Molinie V
and Richaud P: Addition of radiotherapy to long-term androgen
deprivation in locally advanced prostate cancer: an open randomised
phase 3 trial. Eur Urol. 62:213–219. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Warde P, Mason M, Ding K, et al: NCIC CTG
PR.3/MRC UK PR07 Investigators: Combined androgen deprivation
therapy and radiation therapy for locally advanced prostate cancer:
a randomised, phase 3 trial. Lancet. 378:2104–2111. 2011.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Widmark A, Klepp O, Solberg A, et al:
Scandinavian Prostate Cancer Group Study 7; Swedish Association for
Urological Oncology 3: Endocrine treatment, with or without
radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3):
an open randomised phase III trial. Lancet. 373:301–308. 2009.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Albertsen PC, Hanley JA, Barrows GH, et
al: Prostate cancer and the Will Rogers phenomenon. J Natl Cancer
Inst. 97:1248–1253. 2005. View Article : Google Scholar : PubMed/NCBI
|
20
|
Horwitz EM, Bae K, Hanks GE, et al:
Ten-year follow-up of radiation therapy oncology group protocol
92–02: a phase III trial of the duration of elective androgen
deprivation in locally advanced prostate cancer. J Clin Oncol.
26:2497–2504. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Nanda A, Chen MH, Braccioforte MH, Moran
BJ and D'Amico AV: Hormonal therapy use for prostate cancer and
mortality in men with coronary artery disease-induced congestive
heart failure or myocardial infarction. JAMA. 302:866–873. 2009.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Lawton CA, DeSilvio M, Roach M III, et al:
An update of the phase III trial comparing whole pelvic to prostate
only radiotherapy and neoadjuvant to adjuvant total androgen
suppression: updated analysis of RTOG 94–13, with emphasis on
unexpected hormone/radiation interactions. Int J Radiat Oncol Biol
Phys. 69:646–655. 2007. View Article : Google Scholar : PubMed/NCBI
|